HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Monday, 11 November 2013

New project: NICE TA of adalimumab and infliximab for Crohn’s

ScHARR-TAG has been allocated the following topic as part of the NICE Technology Appraisal Programme:

Adalimumab and infliximab (2nd line) for Crohn’s disease (moderate, active)

Interestingly, the draft scope includes biosimilars within the appraisal – the European Commission has recently approved the first infliximab biosimilars.  How the evidence on these products will be factored in should be interesting…….